Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 17/20 | 0.43 |
| ▸ | CCND1 | P24385 | 17/20 | 0.43 |
| ▸ | CDK2 | P24941 | 12/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 9/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 9/20 | 0.43 |
| ▸ | CCND2 | P30279 | 4/20 | 0.43 |
| ▸ | CCND3 | P30281 | 4/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041718 | 0.79 | PAK3 (0.35) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL15281050 | 0.78 | CCND1 (0.40) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL15281036 | 0.77 | CDK4 (0.42) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL15041659 | 0.76 | CDK4 (0.43) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL13553797 | 0.75 | CDK4 (0.49) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL15035999 | 0.74 | CCND1 (0.41) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL15036108 | 0.72 | PAK1 (0.39) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL14682006 | 0.71 | FGFR1 (0.48) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL15041613 | 0.71 | CDK4 (0.36) | CDK4CCND1CDK2CCNA2FGFR1 | |
| SCHEMBL16309185 | 0.71 | RIPK2 (0.41) | CDK4CCND1FGFR1CCND2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | CDK4 471/4885CCND1 4379/4885CDK2 226/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CDK4 404/4885CCND1 2153/4885CDK2 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.